TY - JOUR
T1 - Association of innate immune activation with latent epstein-barr virus in active MS lesions
AU - Tzartos, J. S.
AU - Khan, G.
AU - Vossenkamper, A.
AU - Cruz-Sadaba, M.
AU - Lonardi, S.
AU - Sefia, E.
AU - Meager, A.
AU - Elia, A.
AU - Middeldorp, J. M.
AU - Clemens, M.
AU - Farrell, P. J.
AU - Giovannoni, G.
AU - Meier, U. C.
N1 - Funding Information:
Dr. Tzartos has a patent pending re: Methods for detecting the presence of target molecules in a biological sample. Prof. Khan reports no disclosures. Dr. Vossenkamper receives research support from the Medical Research Council, UK. Dr. Cruz-Sadaba receives research support from the Medical Research Council, UK. Dr. Lonardi and E. Sefia report no disclosures. Dr. Meager serves on the editorial board of the Journal of Interferon and Cytokine Research and receives publishing royalties for The Interferons: Characterization and Application (Wiley-VCH Verlag GmbH & Co. KGaA, 2006). Dr. Elia receives research support from The Wellcome Trust. Prof. Middeldorp reports no disclosures. Prof. Clemens receives research support from The Wellcome Trust. Prof. Farrell serves on the editorial boards of the Journal of Virology and the Journal of General Virology and receives research support from Leukaemia and Lymphoma Research, UK. Prof. Giovannoni serves on scientific advisory boards for Merck Serono and Biogen Idec and Vertex Pharmaceuticals; served on the editorial board of Multiple Sclerosis ; has received speaker honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Pfizer Inc, Teva Pharmaceutical Industries Ltd.–sanofi-aventis, Vertex Pharmaceuticals, Genzyme Corporation, Ironwood, and Novartis; has served as a consultant for Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Merck Serono, Protein Discovery Laboratories, Teva Pharmaceutical Industries Ltd.–sanofi-aventis, UCB, Vertex Pharmaceuticals, GW Pharma, Novartis, and FivePrime; serves on the speakers bureau for Merck Serono; and has received research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, UCB, Merz Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd.–sanofi-aventis, GW Pharma, and Ironwood. Dr. Meier receives research support from British Technology Group, ABN/MS Society, Aims2Cure, and the Roan Charitable Trust.
PY - 2012/1/3
Y1 - 2012/1/3
N2 - Objective: To determine whether the activation of innate immune responses, which can be elicited by pathogenic and endogenous triggers, is associated with the presence of Epstein-Barr virus (EBV) infection in the multiple sclerosis (MS) brain. Methods: White matter postmortem MS (n = 10) and control tissue (n = 11) was analyzed for the expression of the proinflammatory cytokine interferon α (IFNα) by immunohistochemistry and for EBV by using the highly sensitive method of EBV-encoded RNA (EBER) in situ hybridization. Results: We detected overexpression of IFNα in active areas of white matter MS lesions but not in inactive MS lesions, normal-appearing white matter, or normal brains. The presence of IFNα in macrophages and microglia (expressing human leukocyte antigen class II) is suggestive of local production as part of an acute inflammatory process. Interestingly, EBERs were also specifically detected in areas where IFNα was overexpressed in these preselected active MS lesions. EBER+ cells were also found in CNS lymphoma and stroke cases, but were absent in other control brains. We next addressed a potential mechanism, e.g., the role of EBERs in eliciting IFNα production, and transfected EBERs into human embryonic kidney (HEK) cells. We used HEK cells that stably expressed Toll-like receptor-3, which recognizes double-stranded RNAs, associated with many viral infections. EBERs elicited IFNα production in vitro. Conclusion: These findings suggest that latent EBV infection may contribute to the inflammatory milieu in active MS lesions by activating innate immune responses, e.g., IFNα production. Unraveling the underlying mechanisms may help in uncovering causal pathways and developing better treatment strategies for MS and other neuroinflammatory diseases.
AB - Objective: To determine whether the activation of innate immune responses, which can be elicited by pathogenic and endogenous triggers, is associated with the presence of Epstein-Barr virus (EBV) infection in the multiple sclerosis (MS) brain. Methods: White matter postmortem MS (n = 10) and control tissue (n = 11) was analyzed for the expression of the proinflammatory cytokine interferon α (IFNα) by immunohistochemistry and for EBV by using the highly sensitive method of EBV-encoded RNA (EBER) in situ hybridization. Results: We detected overexpression of IFNα in active areas of white matter MS lesions but not in inactive MS lesions, normal-appearing white matter, or normal brains. The presence of IFNα in macrophages and microglia (expressing human leukocyte antigen class II) is suggestive of local production as part of an acute inflammatory process. Interestingly, EBERs were also specifically detected in areas where IFNα was overexpressed in these preselected active MS lesions. EBER+ cells were also found in CNS lymphoma and stroke cases, but were absent in other control brains. We next addressed a potential mechanism, e.g., the role of EBERs in eliciting IFNα production, and transfected EBERs into human embryonic kidney (HEK) cells. We used HEK cells that stably expressed Toll-like receptor-3, which recognizes double-stranded RNAs, associated with many viral infections. EBERs elicited IFNα production in vitro. Conclusion: These findings suggest that latent EBV infection may contribute to the inflammatory milieu in active MS lesions by activating innate immune responses, e.g., IFNα production. Unraveling the underlying mechanisms may help in uncovering causal pathways and developing better treatment strategies for MS and other neuroinflammatory diseases.
UR - http://www.scopus.com/inward/record.url?scp=84856605958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856605958&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e31823ed057
DO - 10.1212/WNL.0b013e31823ed057
M3 - Article
C2 - 22156987
AN - SCOPUS:84856605958
SN - 0028-3878
VL - 78
SP - 15
EP - 23
JO - Neurology
JF - Neurology
IS - 1
ER -